Expression of tenascin-C and its isoforms in the breast (original) (raw)

References

1. Bissell, M. J., & Radisky, D. (2001). Putting tumours in context. Nature Reviews Cancer, 1, 46–54.
   CAS PubMed Google Scholar
2. Liotta, L. A., & Kohn, E. C. (2001). The microenvironment of the tumour–host interface. Nature, 411, 375–379.
   CAS PubMed Google Scholar
3. de Visser, K. E., & Coussens, L. M. (2006). The inflammatory tumor microenvironment and its impact on cancer development. Contributions to Microbiology, 13, 118–137.
   PubMed Google Scholar
4. Egeblad, M., Littlepage, L. E., & Werb, Z. (2005). The fibroblastic coconspirator in cancer progression. Cold Spring Harbor Symposia on Quantative Biology, 70, 383–388.
   CAS Google Scholar
5. Ma, X. J., Dahiya, S., Richardson, E., Erlander, M., & Sgroi, D. C. (2009). Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Research, 11, R7.
   PubMed Google Scholar
6. Kalluri, R., & Zeisberg, M. (2006). Fibroblasts in cancer. Nature Reviews Cancer, 6, 392–401.
   CAS PubMed Google Scholar
7. Carnemolla, B., Castellani, P., Ponassi, M., Borsi, L., Urbini, S., Nicolo, G., et al. (1999). Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. American Journal of Pathology, 154, 1345–1352.
   CAS PubMed Google Scholar
8. Fuss, B., Pott, U., Fischer, P., Schwab, M. E., & Schachner, M. (1991). Identification of a cDNA clone specific for the oligodendrocyte-derived repulsive extracellular matrix molecule J1-160/180. Journal of Neuroscience Research, 29, 299–307.
   CAS PubMed Google Scholar
9. Weber, P., Montag, D., Schachner, M., & Bernhardt, R. R. (1998). Zebrafish tenascin-W, a new member of the tenascin family. Journal of Neurobiology, 35, 1–16.
   CAS PubMed Google Scholar
10. Scherberich, A., Tucker, R. P., Degen, M., Brown-Luedi, M., Andres, A. C., & Chiquet-Ehrismann, R. (2005). Tenascin-W is found in malignant mammary tumors, promotes alpha8 integrin-dependent motility and requires p38MAPK activity for BMP-2 and TNF-alpha induced expression in vitro. Oncogene, 24, 1525–1532.
    CAS PubMed Google Scholar
11. Degen, M., Brellier, F., Kain, R., Ruiz, C., Terracciano, L., Orend, G., et al. (2007). Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Research, 67, 9169–9179.
    CAS PubMed Google Scholar
12. Bristow, J., Tee, M. K., Gitelman, S. E., Mellon, S. H., & Miller, W. L. (1993). Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. Journal of Cell Biology, 122, 265–278.
    CAS PubMed Google Scholar
13. Mao, J. R., Taylor, G., Dean, W. B., Wagner, D. R., Afzal, V., Lotz, J. C., et al. (2002). Tenascin-X deficiency mimics Ehlers–Danlos syndrome in mice through alteration of collagen deposition. Nature Genetics, 30, 421–425.
    CAS PubMed Google Scholar
14. Burch, G. H., Gong, Y., Liu, W., Dettman, R. W., Curry, C. J., Smith, L., et al. (1997). Tenascin-X deficiency is associated with Ehlers–Danlos syndrome. Nature Genetics, 17, 104–108.
    CAS PubMed Google Scholar
15. Hagios, C., Koch, M., Spring, J., Chiquet, M., & Chiquet-Ehrismann, R. (1996). Tenascin-Y: A protein of novel domain structure is secreted by differentiated fibroblasts of muscle connective tissue. Journal of Cell Biology, 134, 1499–1512.
    CAS PubMed Google Scholar
16. Chiquet-Ehrismann, R. (2004). Tenascins. International Journal of Biochemistry & Cell Biology, 36, 986–990.
    CAS Google Scholar
17. Chiquet-Ehrismann, R., & Chiquet, M. (2003). Tenascins: Regulation and putative functions during pathological stress. Journal of Pathology, 200, 488–499.
    CAS PubMed Google Scholar
18. Hsia, H. C., & Schwarzbauer, J. E. (2005). Meet the tenascins: Multifunctional and mysterious. Journal of Biological Chemistry, 280, 26641–26644.
    CAS PubMed Google Scholar
19. Chung, C. Y., Murphy-Ullrich, J. E., & Erickson, H. P. (1996). Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Molecular Biology of the Cell, 7, 883–892.
    CAS PubMed Google Scholar
20. Ghert, M. A., Qi, W. N., Erickson, H. P., Block, J. A., & Scully, S. P. (2001). Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. Cell Structure and Function, 26, 179–187.
    CAS PubMed Google Scholar
21. Midwood, K. S., & Orend, G. (2009). The role of tenascin-C in tissue injury and tumorigenesis. Journal of Cell Communication and Signaling, 3, 287–310.
    PubMed Google Scholar
22. Jones, P. L., & Jones, F. S. (2000). Tenascin-C in development and disease: Gene regulation and cell function. Matrix Biology, 19, 581–596.
    CAS PubMed Google Scholar
23. Jones, F. S., & Jones, P. L. (2000). The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling. Developmental Dynamics, 218, 235–259.
    CAS PubMed Google Scholar
24. Erickson, H. P., & Inglesias, J. L. (1984). A six-armed oligomer isolated from cell surface fibronectin preparations. Nature, 311, 267–269.
    CAS PubMed Google Scholar
25. Hancox, R. A., Allen, M. D., Holliday, D. L., Edwards, D. R., Pennington, C. J., Guttery, D. S., et al. (2009). Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Research, 11, R24.
    PubMed Google Scholar
26. Orend, G., & Chiquet-Ehrismann, R. (2006). Tenascin-C induced signaling in cancer. Cancer Letters, 244, 143–163.
    CAS PubMed Google Scholar
27. Howeedy, A. A., Virtanen, I., Laitinen, L., Gould, N. S., Koukoulis, G. K., & Gould, V. E. (1990). Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast. Laboratory Investigation, 63, 798–806.
    CAS PubMed Google Scholar
28. Jahkola, T., Toivonen, T., Virtanen, I., von Smitten, K., Nordling, S., von Boguslawski, K., et al. (1998). Tenascin-C expression in invasion border of early breast cancer: A predictor of local and distant recurrence. British Journal of Cancer, 78, 1507–1513.
    CAS PubMed Google Scholar
29. Adams, M., Jones, J. L., Walker, R. A., Pringle, J. H., & Bell, S. C. (2002). Changes in tenascin-C isoform expression in invasive and preinvasive breast disease. Cancer Research, 62, 3289–3297.
    CAS PubMed Google Scholar
30. Murphy-Ullrich, J. E., Lightner, V. A., Aukhil, I., Yan, Y. Z., Erickson, H. P., & Hook, M. (1991). Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. Journal of Cell Biology, 115, 1127–1136.
    CAS PubMed Google Scholar
31. Phillips, G. R., Krushel, L. A., & Crossin, K. L. (1998). Domains of tenascin involved in glioma migration. Journal of Cell Science, 111(Pt 8), 1095–1104.
    CAS PubMed Google Scholar
32. Taraseviciute, A., Vincent, B. T., Schedin, P., & Jones, P. L. (2010). Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. American Journal of Pathology, 176, 827–838.
    CAS PubMed Google Scholar
33. Chiquet-Ehrismann, R., Mackie, E. J., Pearson, C. A., & Sakakura, T. (1986). Tenascin: An extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell, 47, 131–139.
    CAS PubMed Google Scholar
34. Russo, J., & Russo, I. H. (1996). Experimentally induced mammary tumors in rats. Breast Cancer Research and Treatment, 39, 7–20.
    CAS PubMed Google Scholar
35. Tsubura, A., Yoshizawa, K., Uehara, N., Yuri, T., & Matsuoka, Y. (2007). Multistep mouse mammary tumorigenesis through pre-neoplasia to neoplasia and acquisition of metastatic potential. Medical Molecular Morphology, 40, 9–17.
    PubMed Google Scholar
36. Mackie, E. J., Chiquet-Ehrismann, R., Adams Pearson, C., Inaguma, Y., Taya, K., Kawarada, Y., et al. (1987). Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proceedings of the National Academy of Sciences U S A, 84, 4621–4625.
    CAS Google Scholar
37. Inaguma, Y., Kusakabe, M., Mackie, E. J., Pearson, C. A., Chiquet-Ehrismann, R., & Sakakura, T. (1988). Epithelial induction of stromal tenascin in the mouse mammary gland: From embryogenesis to carcinogenesis. Developmental Biology, 128, 245–255.
    CAS PubMed Google Scholar
38. Bell, S. C., Pringle, J. H., Taylor, D. J., & Malak, T. M. (1999). Alternatively spliced tenascin-C mRNA isoforms in human fetal membranes. Molecular Human Reproduction, 5, 1066–1076.
    CAS PubMed Google Scholar
39. Erickson, H. P., & Bourdon, M. A. (1989). Tenascin: An extracellular matrix protein prominent in specialized embryonic tissues and tumors. Annual Review of Cell Biology, 5, 71–92.
    CAS PubMed Google Scholar
40. Erickson, H. P., & Lightner, V. A. (1988). Hexabrachion protein (tenascin, cytotactin, brachionectin) in connective tissues, embryonic brain, and tumors. Advanced Cell Biology, 2, 55–90.
    Google Scholar
41. Chiquet-Ehrismann, R., Kalla, P., & Pearson, C. A. (1989). Participation of tenascin and transforming growth factor-beta in reciprocal epithelial–mesenchymal interactions of MCF7 cells and fibroblasts. Cancer Research, 49, 4322–4325.
    CAS PubMed Google Scholar
42. Maschler, S., Grunert, S., Danielopol, A., Beug, H., & Wirl, G. (2004). Enhanced tenascin-C expression and matrix deposition during Ras/TGF-beta-induced progression of mammary tumor cells. Oncogene, 23, 3622–3633.
    CAS PubMed Google Scholar
43. Kawakatsu, H., Shiurba, R., Obara, M., Hiraiwa, H., Kusakabe, M., & Sakakura, T. (1992). Human carcinoma cells synthesize and secrete tenascin in vitro. Japanese Journal of Cancer Research, 83, 1073–1080.
    CAS PubMed Google Scholar
44. Lightner, V. A., Marks, J. R., & McCachren, S. S. (1994). Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Experimental Cell Research, 210, 177–184.
    CAS PubMed Google Scholar
45. Dandachi, N., Hauser-Kronberger, C., More, E., Wiesener, B., Hacker, G. W., Dietze, O., et al. (2001). Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: Correlation with histopathological parameters, hormone receptors, and oncoproteins. Journal of Pathology, 193, 181–189.
    CAS PubMed Google Scholar
46. Gordon, L. A., Mulligan, K. T., Maxwell-Jones, H., Adams, M., Walker, R. A., & Jones, J. L. (2003). Breast cell invasive potential relates to the myoepithelial phenotype. International Journal of Cancer, 106, 8–16.
    CAS Google Scholar
47. Jahkola, T., Toivonen, T., von Smitten, K., Blomqvist, C., & Virtanen, I. (1996). Expression of Tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. International Journal of Cancer, 69, 445–447.
    CAS Google Scholar
48. Jahkola, T. (1998). Self-perceptions of women after early breast cancer surgery. European Journal of Surgical Oncology, 24, 9–14.
    CAS PubMed Google Scholar
49. Shoji, T., Kamiya, T., Tsubura, A., Hatano, T., Sakakura, T., Yamamoto, M., et al. (1992). Immunohistochemical staining patterns of tenascin in invasive breast carcinomas. Virchows Archiv. A, Pathological Anatomy and Histopathology, 421, 53–56.
    CAS PubMed Google Scholar
50. Ferguson, J. E., Schor, A. M., Howell, A., & Ferguson, M. W. (1990). Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. Differentiation, 42, 199–207.
    CAS PubMed Google Scholar
51. Vollmer, G., Siegal, G. P., Chiquet-Ehrismann, R., Lightner, V. A., Arnholdt, H., & Knuppen, R. (1990). Tenascin expression in the human endometrium and in endometrial adenocarcinomas. Laboratory Investigation, 62, 725–730.
    CAS PubMed Google Scholar
52. Jahkola, T., Toivonen, T., Nordling, S., von Smitten, K., & Virtanen, I. (1998). Expression of tenascin-C in intraductal carcinoma of human breast: Relationship to invasion. European Journal of Cancer, 34, 1687–1692.
    CAS PubMed Google Scholar
53. Goepel, C., Buchmann, J., Schultka, R., & Koelbl, H. (2000). Tenascin-A marker for the malignant potential of preinvasive breast cancers. Gynecologic Oncology, 79, 372–378.
    CAS PubMed Google Scholar
54. Tokes, A. M., Paku, S., Toth, S., Paal, E., Kulka, J., Toth, J., et al. (2000). Tenascin expression in primary and recurrent breast carcinomas and the effect of tenascin on breast tumor cell cultures. Pathology and Oncology Research, 6, 202–209.
    CAS PubMed Google Scholar
55. Gould, V. E., Koukoulis, G. K., & Virtanen, I. (1990). Extracellular matrix proteins and their receptors in the normal, hyperplastic and neoplastic breast. Cell Differentiation and Development, 32, 409–416.
    CAS PubMed Google Scholar
56. Koukoulis, G. K., Gould, V. E., Bhattacharyya, A., Gould, J. E., Howeedy, A. A., & Virtanen, I. (1991). Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: Biologic and pathologic implications. Human Pathology, 22, 636–643.
    CAS PubMed Google Scholar
57. Moch, H., Torhorst, J., Durmuller, U., Feichter, G. E., Sauter, G., & Gudat, F. (1993). Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer. Pathology, Research and Practice, 189, 510–514.
    CAS PubMed Google Scholar
58. Natali, P. G., Nicotra, M. R., Bigotti, A., Botti, C., Castellani, P., Risso, A. M., et al. (1991). Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. International Journal of Cancer, 47, 811–816.
    CAS Google Scholar
59. Shrestha, P., Sakamoto, F., Takagi, H., Yamada, T., & Mori, M. (1994). Enhanced tenascin immunoreactivity in leukoplakia and squamous cell carcinoma of the oral cavity: An immunohistochemical study. European Journal of Cancer Part B: Oral Oncology, 30B, 132–137.
    CAS Google Scholar
60. Shrestha, P., Sumitomo, S., Ogata, K., Yamada, K., Takai, Y., Yang, L., et al. (1994). Immunoreactive tenascin in tumours of salivary glands: Evidence for enhanced expression in tumour stroma and production by tumour cells. European Journal of Cancer Part B: Oral Oncology, 30B, 393–399.
    CAS Google Scholar
61. Yamanaka, M., Taga, M., & Minaguchi, H. (1996). Immunohistological localization of tenascin in the human endometrium. Gynecologic and Obstetric Investigation, 41, 247–252.
    CAS PubMed Google Scholar
62. Weigelt, B., Peterse, J. L., & van’t Veer, L. J. (2005). Breast cancer metastasis: Markers and models. Nature Reviews Cancer, 5, 591–602.
    CAS PubMed Google Scholar
63. Joyce, J. A., & Pollard, J. W. (2009). Microenvironmental regulation of metastasis. Nature Reviews Cancer, 9, 239–252.
    CAS PubMed Google Scholar
64. Tsunoda, T., Inada, H., Kalembeyi, I., Imanaka-Yoshida, K., Sakakibara, M., Okada, R., et al. (2003). Involvement of large tenascin-C splice variants in breast cancer progression. American Journal of Pathology, 162, 1857–1867.
    CAS PubMed Google Scholar
65. Emoto, K., Yamada, Y., Sawada, H., Fujimoto, H., Ueno, M., Takayama, T., et al. (2001). Annexin II overexpression correlates with stromal tenascin-C overexpression: A prognostic marker in colorectal carcinoma. Cancer, 92, 1419–1426.
    CAS PubMed Google Scholar
66. Kusagawa, H., Onoda, K., Namikawa, S., Yada, I., Okada, A., Yoshida, T., et al. (1998). Expression and degeneration of tenascin-C in human lung cancers. British Journal of Cancer, 77, 98–102.
    CAS PubMed Google Scholar
67. Leins, A., Riva, P., Lindstedt, R., Davidoff, M. S., Mehraein, P., & Weis, S. (2003). Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer, 98, 2430–2439.
    CAS PubMed Google Scholar
68. Ioachim, E., Charchanti, A., Briasoulis, E., Karavasilis, V., Tsanou, H., Arvanitis, D. L., et al. (2002). Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: Their prognostic value and role in tumour invasion and progression. European Journal of Cancer, 38, 2362–2370.
    CAS PubMed Google Scholar
69. Thiery, J. P. (2002). Epithelial–mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2, 442–454.
    CAS PubMed Google Scholar
70. Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., Bos, P. D., et al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 451, 147–152.
    CAS PubMed Google Scholar
71. Sugawara, I., Hirakoshi, J., Masunaga, A., Itoyama, S., & Sakakura, T. (1991). Reduced tenascin expression in colonic carcinoma with lymphogenous metastasis. Invasion and Metastasis, 11, 325–331.
    CAS Google Scholar
72. Shoji, T., Kamiya, T., Tsubura, A., Hamada, Y., Hatano, T., Hioki, K., et al. (1993). Tenascin staining positivity and the survival of patients with invasive breast carcinoma. Journal of Surgical Research, 55, 295–297.
    CAS PubMed Google Scholar
73. Ishihara, A., Yoshida, T., Tamaki, H., & Sakakura, T. (1995). Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clinical Cancer Research, 1, 1035–1041.
    CAS PubMed Google Scholar
74. Tiitta, O., Wahlstrom, T., Paavonen, J., Linnala, A., Sharma, S., Gould, V. E., et al. (1992). Enhanced tenascin expression in cervical and vulvar koilocytotic lesions. American Journal of Pathology, 141, 907–913.
    CAS PubMed Google Scholar
75. Helleman, J., Jansen, M. P., Ruigrok-Ritstier, K., van Staveren, I. L., Look, M. P., Meijer-van Gelder, M. E., et al. (2008). Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clinical Cancer Research, 14, 5555–5564.
    CAS PubMed Google Scholar
76. Joester, A., & Faissner, A. (1999). Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system. Journal of Biological Chemistry, 274, 17144–17151.
    CAS PubMed Google Scholar
77. von Holst, A., Egbers, U., Prochiantz, A., & Faissner, A. (2007). Neural stem/progenitor cells express 20 tenascin C isoforms that are differentially regulated by Pax6. Journal of Biological Chemistry, 282, 9172–9181.
    Google Scholar
78. Dorries, U., & Schachner, M. (1994). Tenascin mRNA isoforms in the developing mouse brain. Journal of Neuroscience Research, 37, 336–347.
    CAS PubMed Google Scholar
79. Chiquet-Ehrismann, R., Matsuoka, Y., Hofer, U., Spring, J., Bernasconi, C., & Chiquet, M. (1991). Tenascin variants: Differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regulation, 2, 927–938.
    CAS PubMed Google Scholar
80. Kaplony, A., Zimmermann, D. R., Fischer, R. W., Imhof, B. A., Odermatt, B. F., Winterhalter, K. H., et al. (1991). Tenascin Mr 220000 isoform expression correlates with corneal cell migration. Development, 112, 605–614.
    CAS PubMed Google Scholar
81. Prieto, A. L., Jones, F. S., Cunningham, B. A., Crossin, K. L., & Edelman, G. M. (1990). Localization during development of alternatively spliced forms of cytotactin mRNA by in situ hybridization. Journal of Cell Biology, 111, 685–698.
    CAS PubMed Google Scholar
82. Tucker, R. P. (1991). The sequential expression of tenascin mRNA in epithelium and mesenchyme during feather morphogenesis. Roux’s Archives of Developmental Biology, 200, 108–112.
    Google Scholar
83. Weller, A., Beck, S., & Ekblom, P. (1991). Amino acid sequence of mouse tenascin and differential expression of two tenascin isoforms during embryogenesis. Journal of Cell Biology, 112, 355–362.
    CAS PubMed Google Scholar
84. Joester, A., & Faissner, A. (2001). The structure and function of tenascins in the nervous system. Matrix Biology, 20, 13–22.
    CAS PubMed Google Scholar
85. Borsi, L., Balza, E., Castellani, P., Carnemolla, B., Ponassi, M., Querze, G., et al. (1994). Cell-cycle dependent alternative splicing of the tenascin primary transcript. Cell Adhesion and Communication, 1, 307–317.
    CAS PubMed Google Scholar
86. Borsi, L., Allemanni, G., Gaggero, B., & Zardi, L. (1996). Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells. International Journal of Cancer, 66, 632–635.
    CAS Google Scholar
87. Vollmer, G., Tan, M. I., Wunsche, W., & Frank, K. (1997). Expression of tenascin-C by human endometrial adenocarcinoma and stroma cells: Heterogeneity of splice variants and induction by TGF-beta. Biochemistry and Cell Biology, 75, 759–769.
    CAS PubMed Google Scholar
88. Chung, C. Y., & Erickson, H. P. (1994). Cell surface annexin II is a high affinity receptor for the alternatively spliced segment of tenascin-C. Journal of Cell Biology, 126, 539–548.
    CAS PubMed Google Scholar
89. Huang, W., Chiquet-Ehrismann, R., Moyano, J. V., Garcia-Pardo, A., & Orend, G. (2001). Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Research, 61, 8586–8594.
    CAS PubMed Google Scholar
90. Lange, K., Kammerer, M., Saupe, F., Hegi, M. E., Grotegut, S., Fluri, E., et al. (2008). Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Research, 68, 6942–6952.
    CAS PubMed Google Scholar
91. Orend, G., Huang, W., Olayioye, M. A., Hynes, N. E., & Chiquet-Ehrismann, R. (2003). Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene, 22, 3917–3926.
    CAS PubMed Google Scholar
92. Ruiz, C., Huang, W., Hegi, M. E., Lange, K., Hamou, M. F., Fluri, E., et al. (2004). Growth promoting signaling by tenascin-C [corrected]. Cancer Research, 64, 7377–7385.
    CAS PubMed Google Scholar
93. Crossin, K. L. (1996). Tenascin: A multifunctional extracellular matrix protein with a restricted distribution in development and disease. Journal of Cellular Biochemistry, 61, 592–598.
    CAS PubMed Google Scholar
94. Prieto, A. L., Andersson-Fisone, C., & Crossin, K. L. (1992). Characterization of multiple adhesive and counteradhesive domains in the extracellular matrix protein cytotactin. Journal of Cell Biology, 119, 663–678.
    CAS PubMed Google Scholar
95. Sriramarao, P., Mendler, M., & Bourdon, M. A. (1993). Endothelial cell attachment and spreading on human tenascin is mediated by alpha 2 beta 1 and alpha v beta 3 integrins. Journal of Cell Science, 105(Pt 4), 1001–1012.
    CAS PubMed Google Scholar
96. Fischer, D., Tucker, R. P., Chiquet-Ehrismann, R., & Adams, J. C. (1997). Cell-adhesive responses to tenascin-C splice variants involve formation of fascin microspikes. Molecular Biology of the Cell, 8, 2055–2075.
    CAS PubMed Google Scholar
97. Gotz, M., Bolz, J., Joester, A., & Faissner, A. (1997). Tenascin-C synthesis and influence on axonal growth during rat cortical development. European Journal of Neuroscience, 9, 496–506.
    CAS PubMed Google Scholar
98. Hauzenberger, D., Olivier, P., Gundersen, D., & Ruegg, C. (1999). Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1–5 repeats to fibronectin. European Journal of Immunology, 29, 1435–1447.
    CAS PubMed Google Scholar
99. Julian, J., Chiquet-Ehrismann, R., Erickson, H. P., & Carson, D. D. (1994). Tenascin is induced at implantation sites in the mouse uterus and interferes with epithelial cell adhesion. Development, 120, 661–671.
    CAS PubMed Google Scholar
100. Krushel, L. A., Prieto, A. L., Edelman, G. M., & Crossin, K. L. (1994). Differential effects of cytotactin tenascin fusion proteins on intracellular pH and cell morphology. Journal of Cellular Physiology, 161, 508–518.
     CAS PubMed Google Scholar
101. Spring, J., Beck, K., & Chiquet-Ehrismann, R. (1989). Two contrary functions of tenascin: Dissection of the active sites by recombinant tenascin fragments. Cell, 59, 325–334.
     CAS PubMed Google Scholar
102. Borsi, L., Carnemolla, B., Nicolo, G., Spina, B., Tanara, G., & Zardi, L. (1992). Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. International Journal of Cancer, 52, 688–692.
     CAS Google Scholar
103. Richter, P. T. M., Franz, M., Altendorf-Hofmann, A., Junker, K., Borsi, L., Neri, D., et al. (2009). B and C domain containing tenascin-C: Urinary markers for invasiveness of urothelial carcinoma of the urinary bladder? Journal of Cancer Research and Clinical Oncology, 135, 1351–1358.
     CAS PubMed Google Scholar
104. Berndt, A., Anger, K., Richter, P., Borsi, L., Brack, S., Silacci, M., et al. (2006). Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder. Journal of Cancer Research and Clinical Oncology, 132, 537–546.
     CAS PubMed Google Scholar
105. Herold-Mende, C., Mueller, M. M., Bonsanto, M. M., Schmitt, H. P., Kunze, S., & Steiner, H. H. (2002). Clinical impact and functional aspects of tenascin-C expression during glioma progression. International Journal of Cancer, 98, 362–369.
     CAS Google Scholar
106. Gazzaniga, P., Nofroni, I., Gandini, O., Silvestri, I., Frati, L., Agliano, A. M., et al. (2005). Tenascin C and epidermal growth factor receptor as markers of circulating tumoral cells in bladder and colon cancer. Oncology Reports, 14, 1199–1202.
     CAS PubMed Google Scholar
107. Parekh, K., Ramachandran, S., Cooper, J., Bigner, D., Patterson, A., & Mohanakumar, T. (2005). Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. Lung Cancer, 47, 17–29.
     PubMed Google Scholar
108. Sis, B., Tuna, B., Yorukoglu, K., & Kargi, A. (2004). Tenascin C and cathepsin d expression in adipocytic tumors: an immunohistochemical investigation of 43 cases. International Journal of Surgical Pathology, 12, 11–15.
     CAS PubMed Google Scholar
109. Vacca, A., Ribatti, D., Fanelli, M., Costantino, F., Nico, B., Di Stefano, R., et al. (1996). Expression of tenascin is related to histologic malignancy and angiogenesis in b-cell non-Hodgkin’s lymphomas. Leukemia and Lymphoma, 22, 473–481.
     CAS PubMed Google Scholar
110. Pilch, H., Schaffer, U., Schlenger, K., Lautz, A., Tanner, B., Hockel, M., et al. (1999). Expression of tenascin in human cervical cancer-association of tenascin expression with clinicopathological parameters. Gynecologic Oncology, 73, 415–421.
     CAS PubMed Google Scholar
111. Iskaros, B. E., Sison, C. P., & Hajdu, S. I. (2000). Tenascin patterns of expression in duct carcinoma in situ of the breast. Annals of Clinical and Laboratory Science, 30, 266–271.
     CAS PubMed Google Scholar
112. Wilson, K. E., Langdon, S. P., Lessells, A. M., & Miller, W. R. (1996). Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. British Journal of Cancer, 74, 999–1004.
     CAS PubMed Google Scholar
113. Meiners, S., Nur-e-Kamal, M. S., & Mercado, M. L. (2001). Identification of a neurite outgrowth-promoting motif within the alternatively spliced region of human tenascin-C. Journal of Neuroscience, 21, 7215–7225.
     CAS PubMed Google Scholar
114. Mercado, M. L., Nur-e-Kamal, A., Liu, H. Y., Gross, S. R., Movahed, R., & Meiners, S. (2004). Neurite outgrowth by the alternatively spliced region of human tenascin-C is mediated by neuronal alpha7beta1 integrin. Journal of Neuroscience, 24, 238–247.
     CAS PubMed Google Scholar
115. Rigato, F., Garwood, J., Calco, V., Heck, N., Faivre-Sarrailh, C., & Faissner, A. (2002). Tenascin-C promotes neurite outgrowth of embryonic hippocampal neurons through the alternatively spliced fibronectin type III BD domains via activation of the cell adhesion molecule F3/contactin. Journal of Neuroscience, 22, 6596–6609.
     CAS PubMed Google Scholar
116. Cai, M., Onoda, K., Takao, M., Kyoko, I. Y., Shimpo, H., Yoshida, T., et al. (2002). Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clinical Cancer Research, 8, 1152–1156.
     CAS PubMed Google Scholar
117. Saito, Y., Imazeki, H., Miura, S., Yoshimura, T., Okutsu, H., Harada, Y., et al. (2007). A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. Journal of Biological Chemistry, 282, 34929–34937.
     CAS PubMed Google Scholar
118. Siri, A., Knauper, V., Veirana, N., Caocci, F., Murphy, G., & Zardi, L. (1995). Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. Journal of Biological Chemistry, 270, 8650–8654.
     CAS PubMed Google Scholar
119. Martin, D., Brown-Luedi, M., & Chiquet-Ehrismann, R. (2003). Tenascin-C signaling through induction of 14-3-3 tau. Journal of Cell Biology, 160, 171–175.
     CAS PubMed Google Scholar
120. Sriramarao, P., & Bourdon, M. A. (1993). A novel tenascin type III repeat is part of a complex of tenascin mRNA alternative splices. Nucleic Acids Research, 21, 163–168.
     CAS PubMed Google Scholar
121. Derr, L. B., Chiquet-Ehrismann, R., Gandour-Edwards, R., Spence, J., & Tucker, R. P. (1997). The expression of tenascin-C with the AD1 variable repeat in embryonic tissues, cell lines and tumors in various vertebrate species. Differentiation, 62, 71–82.
     CAS PubMed Google Scholar
122. Tucker, R. P. (1998). Quantitative in situ localization of tenascin-C alternatively spliced transcripts in the avian optic tectum. Molecular Vision, 4, 18.
     CAS PubMed Google Scholar
123. Guttery, D. S., Hancox, R. A., Mulligan, K. T., Hughes, S., Lambe, S. M., Pringle, J. H., et al. (2010). Association of invasion-promoting tenascin-C additional domains with breast cancer in young women. Breast Cancer Research, 12(4), R57.
     Google Scholar

Download references